Table 1.
Cost inputs for the United Kingdom, Germany, and Spain
| Parameter | United Kingdom, $ | Germany, $ | Spain, $ |
|---|---|---|---|
| Treatment (per annum) | |||
| Dapagliflozin | 665 (27) | 898a | 477a |
| Standard therapy | 67 (27) | 39b | 55a |
| Additional monitoring costs (dapagliflozin, first year only) | 202 (29) | 100 (30) | 99 (30) |
| CKD management (per annum) | |||
| CKD G2, 60–89 ml/min per 1.73 m2 | 1689 (31) | 10,207c | 5484 (32) |
| CKD G3a, 45–59 ml/min per 1.73 m2 | 1689 (31) | 10,207 (33) | 5768 (32) |
| CKD G3b, 30–44 ml/min per 1.73 m2 | 1689 (31) | 10,207 (33) | 5768 (34) |
| CKD G4, 15–29 ml/min per 1.73 m2 | 5913 (31) | 12,406 (33) | 9548 (34) |
| CKD G5, not on KRT; <15 ml/min per 1.73 m2 | 20,731 (31) | 56,405 (33) | 16,184 (34) |
| Dialysis | 47,565 (7) | 73,896 (35) | 58,062 (34) |
| Transplant | 28,199 (36) | 146,899 (37) | 26,989 (38) |
| Events | |||
| Hospitalization for heart failure | 7255 (39) | 6576 (40) | 4000 (38) |
| Acute decline in kidney function | 187 (29) | 100 (30) | 99 (30) |
| Volume depletion | 46 (41) | 36 (30) | 3193 (38) |
| Major hypoglycemic event | 514 (42) | 470 (42) | 845 (43) |
| Diabetic ketoacidosis | 3147 (44) | 2911 (44) | 4689 (38) |
| Fracture | 3535 (29) | 8559 (45) | 5173 (46) |
| Amputation | 19,197 (47) | 16,913 (48) | 10,025 (38) |
All prices are inflated to 2021 prices and converted to US dollars using Organisation for Economic Cooperation and Development conversion rates. SEM ranges of 10% are sampled using a γ-distribution in the probabilistic sensitivity analysis.
a
Internal information from AstraZeneca.
b
CompuGroup Medical. Lauer-Taxe. 2022. https://www.cgm.com/deu_de/produkte/apotheke/lauer-taxe.html
c
Assumed to be the same as CKD 3a.